Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07198139
PHASE1/PHASE2

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus

Sponsor: Cocrystal Pharma, Inc.

View on ClinicalTrials.gov

Summary

Participants in this study will be given either CDI-988 or placebo orally before receiving a norovirus challenge virus and continuing for 5 days. Participants will not know whether they are getting placebo or CDI-988. The study will evaluate how well CDI-988 compared to placebo can reduce the incidence of clinical symptoms after a challenge with norovirus. The amount of virus in stool samples will be measured over time. Side effects and pharmacokinetics (the amount of CDI-988 in blood) will also be measured.

Official title: A Phase 1b, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Norovirus

Key Details

Gender

All

Age Range

18 Years - 49 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-03-01

Completion Date

2026-12-01

Last Updated

2026-02-17

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

CDI-988

Antiviral to treat norovirus

DRUG

Placebo

Matching placebo

OTHER

Snow Mountain Virus

Challenge with Snow Mountain Virus

Locations (1)

Hope Clinic of the Emory Vaccine Center

Decatur, Georgia, United States